Drug profile · INN
alogliptin
INCRESYNC
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
alogliptin (INCRESYNC) is an FDA-listed pharmaceutical active ingredient. Associated with Takeda Pharmaceuticals International AG. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN alogliptin
Brand INCRESYNC
Route ORAL
Formulation TABLET
ATC code A10BD13
Originator Takeda Pharmaceuticals International AG
Frequently asked questions
What is alogliptin?
alogliptin (INCRESYNC) is an FDA-listed pharmaceutical active ingredient. Associated with Takeda Pharmaceuticals International AG. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for alogliptin?
INCRESYNC is a marketed brand name for alogliptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of alogliptin?
alogliptin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.